719 related articles for article (PubMed ID: 19422279)
1. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
2. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
Nuijten M; Mittendorf T
Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
[TBL] [Abstract][Full Text] [Related]
4. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
Dashputre AA; Kamal KM; Pawar G
J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
[TBL] [Abstract][Full Text] [Related]
6. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R
J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249
[TBL] [Abstract][Full Text] [Related]
8. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
O'Day K; Meyer K; Stafkey-Mailey D; Watson C
J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
[TBL] [Abstract][Full Text] [Related]
12. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.
Macías-Islas MA; Soria-Cedillo IF; Velazquez-Quintana M; Rivera VM; Baca-Muro VI; Lemus-Carmona EA; Chiquete E
Acta Neurol Belg; 2013 Dec; 113(4):415-20. PubMed ID: 23670405
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Rudick RA; Lublin FD; Weinstock-Guttman B; Wynn DR; Fisher E; Papadopoulou A; Lynn F; Panzara MA; Sandrock AW;
J Neurol Sci; 2010 May; 292(1-2):28-35. PubMed ID: 20236661
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
Agashivala N; Kim E
Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.
Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson KP
Adv Ther; 2009 May; 26(5):552-62. PubMed ID: 19444392
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Hernandez L; Guo S; Kinter E; Fay M
J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
Heisen M; Treur MJ; van der Hel WS; Frequin ST; Groot MT; Verheggen BG
J Med Econ; 2012; 15(6):1149-58. PubMed ID: 22737996
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR
Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]